🚨 OFERTA LABORAL 🚨 Nueva Plaza 🚨
¿Tienes experiencia en Transplante y Terapia Celular?
¿Quieres formar parte de un equipo #ICOnico?

Esta oferta es para ti! 👩🏻‍⚕️👨🏻‍⚕️

INSCRÍBETE AQUÍ!
⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️

icogencat.talentclue.com/ca/node/1203...

@drmiguelperales.bsky.social at #Hemato2025

VII Conferencia Ciril Rozman

#LymphoidWorld
AgoraH Reunion hoy en Madrid!

@sehhematologia.bsky.social #TopHematoRulers! #HematoSpain #HematoMola!

Piropos de verdad! Comentarios que alegran el día y dan sentido al #HematoWorld!

Tratando de inspirar a los #MIR25 desde el ejemplo y los resultados!

5 de mayo! Empieza la selección de plazas! #EligeHematologia! @sehhematologia.bsky.social

Si aún tienes dudas… mis DM están disponibles 24/7

Prizloncabtagene autoleucel: a new CAR T cell for B-NHL In this issue of Blood, Yu et al reported promising clinical results of prizloncabtagene autoleucel (prizlon-cel), a next-generation chimeric antigen recep

New comment on @bloodjournal.bsky.social of our #ICOnic @albertomussetti.bsky.social & @annasureda.bsky.social about Prizloncabtagene autoleucel: New #CART for cell B #Lymphoma!

Available here
⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️
ashpublications.org/blood/articl...

Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC - Bone Marrow Transp... Bone Marrow Transplantation - Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on...

🚨 NEW #ICOnic PUBLICATION 🚨
Congratulations @martape28.bsky.social et al. For this paper!

Now available online
⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️
www.nature.com/articles/s41...

What a great meeting #EBMT25 with a great and #ICOnic participation of Institut Català d’Oncología

Until the next one! See you in Madrid #EBMT26

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee

authors.elsevier.com/a/1ks1w5EIIg...

🚨 New Research Alert! 🚨 A machine learning tool is aiding patients with #myelofibrosis and doctors in making better #transplant decisions! Developed by The EBMT, it outperforms traditional methods. Read more in the press release: www.hematology.org/n...

#Hematology #HemeOnc #HemeSky #MedSky

Patients with Hodgkin lymphoma refractory/intolerant to both BV & checkpoint inhibitors (an increasing reality in the modern era) have median OS 7.4 yrs. This is a new benchmark in novel trials for R/R cHL. Thank you for the opportunity to participate! #lymsm #medsky
www.nature.com/articles/s41...

Post-transplant cyclophosphamide in matched donor transplantation: are we there yet? Graft-versus-host disease (GvHD) is a frequent cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (alloHCT) and…

Post-transplant cyclophosphamide in matched donor transplantation, current state of the art 📌
www.sciencedirect.com/science/arti...

Flyer for FASEB hematologic malignancies meeting. July 27-31 2025. Southbridge Massachusetts. Keynote speakers: Jennifer Trowbridge and George Vassilou

I feel like we could all use something fun to look forward to right about now!!! 🧪🧪🧪

Abstract submission and registration are open for the FASEB Hematologic Malignancies Conference. This is always the BEST meeting!!! Please RT!

events.faseb.org/event/hemato...

🎄Merry Xmas🎄
#HematoRulers around the world! Patients, families and colleagues, my best wishes for all of you!

I know some of you are not at your best moment right now, but all of us are rooting for you! We can do this!

We won’t stop until We’ve beaten Blood Cancer! 💪🏼

If you joined @bsky.app during @ash-hematology.bsky.social #ASH24 here’s a starter pack for transplant, cell & gene therapy #bmtsm #CARTcells #generherapy go.bsky.app/7xxh8WW

#ASH24 plenary: ketogenic diet & CAR-T efficacy
- ketogenic diet➡️cytokine release & CAR expansion in mouse xenograft via beta-hydroxybutyrate
- in pts, BHB correlates w/ CAR expansion and giving BHB to 3 pts enhanced T-cell oxphos
Fascinating! BHB + CAR-T trial is open. #tcellrx

The slide set is almost ready!!

I am excited to present our data at #ASH24 💪🏼 Thank you @ash-hematology.bsky.social for the opportunity and @haemophage.bsky.social for the phenomenal mentorship 🙌🏼

See you all soon 😍

#MedSky

a close up of a woman 's face with a surprised look on her face . ALT: a close up of a woman 's face with a surprised look on her face .

#ASH24 Energy matters! Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate #CARTCell #TCell #tcellrx #immunotherapy @PennMedicine
ash.confex.com/ash/2024/web...

Four haikus, one post,
A cascade of thought and art—
ASH voices converge.

Thanks @stephxie.bsky.social for the #ASH24 #ASHaiku!

17. #MajorPROsASH: Lactuamab CTCL PROs #lymsm
- SS: decreased itch & improved Skindex-29 scores as early as week 5, sustained up to week 45
- MF: PRO improvements occurred later (weeks 29-37)
Differing trajectories of (sustained!) PRO improvements in SS vs MF. #ASH24

16. #MajorPROsASH: STARGLO RCT PROs #lymsm #ASH24
- clinically better pain, lymphoma sx w/ glofi at C3 (both arms sig at C5)
- median time to deterioration of fatigue worse with glofi (1.6 v 4 mos)➡️fatigue d/t glofi?
- EOT: sustained improvements in pain & lymphoma sx both arms

🌟 ABX Pearl of the Day: ESBL cystitis

💡 Q: Can I use amoxicillin/clavulanate to treat ESBL E. coli cystitis if the micro reports it being susceptible?
#IDsky #MedSky #PharmSky #SkyRX #AMSsky

Please join us in welcoming the incoming 2025 ASH President @b-avalos-md.bsky.social to our thriving Bluesky community! #HemeSky #Hematology #ASH24 🎉

20. #MajorPROsASH: CLL13 PROs #leusm
- RV/GV: global QOL w/ sustained improvement
- GIV: QOL did not improve during tx!
- median time to improvement fatigue: ~5 mos in RV/GV/GIV arms
- diarrhea worse with GIV vs all other arms
Worse sx burden with GIV! Stick with GV. #ASH24

Applications for MSK's QSURE 2025 summer #internship program are now open! This program provides undergraduate students hands-on experience in quantitative science research. Applications are due by 5pm ET on 1/18. Apply ⬇️ www.mskcc.org/departments/...

If you haven’t seen it yet, the #ASH24 app allows us to search by disease. I see lots of #hemostasis and #thrombosis to choose from, as well as tons of other other cool science. #hemesky is bright!

Know Before You Go: 66th ASH Annual Meeting and Exposition YouTube video by American Society of Hematology

📹 Make the most of the ASH Annual Meeting — here's what you need to know before you go!

www.youtube.com/watch?v=QGDX...

Learn about registration hours and locations, download the
#ASH24 app, & preview the virtual platform and the new food guide! 😋🍔Check your email.

#HemeSky #Hematology

< 2 wks to #ASH24, here is a📝 of 🔑abstracts from #CommunityOncologists perspective.

- CART Sequencing
- #EpcoreNHL1
- #inMIND
- #EA4151
- #POLARIX
- #CARTITUDE4
- #BMTCTN0702
- #KOMET007
- #LUNA3

#MedEd #mmsm #lymsm #leuksm #HemeSky @ash-hematology.bsky.social #OncSky

ASH-a-Palooza

🌟 Attention trainees! ASH-a-Palooza is just one week away! There’s still time to register for this trainee-focused party full of beats, free bites, & burst of learning. Kicking off #ASH24 next Friday!

Register: bit.ly/ASH-a-Palooza

#ASHTrainee #HemeSky #Hematology #Fellow #MedSky #HemeOnc

#ASH24 of the day:

Talquetamab Bridging before CAR-T

-Talq bridging: 62% ORR (14% CR)
-Post-CAR-T: 97.5% ORR (35% CR)
-Safety: Mild toxicities during talq (no grade ≥3 CRS, 2.5% ICANS)
-Post-CAR-T: less CRS (65%), ICANS (2% grade 3)

Should be standard of care #mmsm @ash-hematology.bsky.social

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Dec 1, 2024 - cc @grpetersen1 - @bdermanmd @bhemato @End_myeloma @HadidiSamer @jmikhaelmd @ManniMD1 @MeeraMohanMD @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani @VincentRK